Market Overview

4 Companies Pfizer Just Increased Its Stake In

Share:

Pfizer Inc. (NYSE: PFE) announced after Friday's market close it has expanded its R&D equity investment strategy to 4 early-stage scientific innovation companies.

There 4 companies include: 1) BioAtla, a company that employs expertise in protein engineering to develop monoclonal antibodies with CAB profiles, 2) NextCure Inc., a bio-pharmaceutical company that focuses on the discovery and development of novel immuno-ongology therapeutic products, 3) Cortexyme, Inc., a company that seeks to develop therapeutics based on a new theory on the acuses of Alzheimer's disease, and 4) 4D Molecular Therapeutics, Inc., a bio-pharmaceutical company that designs, develops and commercializes transformative gene therapy.

"There is exciting scientific discovery happening both within Pfizer and beyond our walls, and we look forward to continuing to explore opportunities to bring our resources to emerging companies investigating in areas where we feel we could make a difference for patients," said Mikael Dolsten, M.D., Ph.D., President of Pfizer Worldwide Research and Development.

"The key for Pfizer is to be flexible in how we partner with different companies; we use a range of investment vehicles and collaboration models in R&D to help ensure we tap into the vast, rapidly-evolving ecosystem of healthcare innovation, looking to complement each other's capabilities so that together we can make a bigger impact."

Shares of Pfizer were trading higher by 0.45 percent at $31.13 early Monday morning.

Posted-In: 4D Molecular Therapeutics BioAtla biotechnology CortexymeBiotech News Startups General

 

Related Articles (PFE)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Highpower Special Committee Engages Roth Capital Partners As Fin. Advisor & Katten Muchin Rosenman LLP as Legal Counsel

Benzinga's Top #PreMarket Losers